Comparative study of Uniform-MDT and WHO MDT in Pauci and Multi bacillary leprosy patients over 24 months of observation

Leprosy Review

Volumn 80, Issue 2, 2009, Pages 143-155

  Rao, P Narasimha ^a,d   Suneetha, Sujai ^b   Pratap, D V S ^c  

^a LEPRA Society   (India)

^b Nireekshana ACET   (India)

^c OSMANIA MEDICAL COLLEGE   (India)

^d NONE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; RIFAMPICIN;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDIA; LEPROMATOUS LEPROSY; MAJOR CLINICAL STUDY; MALE; MULTIBACILLARY LEPROSY; PAUCIBACILLARY LEPROSY; SCHOOL CHILD; SIDE EFFECT; SKIN BIOPSY; SKIN PIGMENTATION; SMEAR; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOID LEPROSY;

ADOLESCENT; ADULT; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDIA; LEPROSTATIC AGENTS; LEPROSY; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349190514     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Report on third meeting of the WHO Technical Advisory Group on Elimination of Leprosy, Brasilia, 1 and 2 February 2002. Geneva: World Health Organization; 2002. (WHO/CDS/CPE/CEE/2002.29).
2. Report on the sixth meeting of the WHO Technical Advisory Group (TAG) on the elimination of leprosy, Geneva, 9 and 10 February 2004. Geneva: World Health Organization; 2004. (WHO/CDS/CPE/CEE/2004.41).
3. Ridley DS. Skin biopsy in leprosy. Histological interpretation and clinical application 2nd edn., Switzerland: Ciba Geigy limited; 1985.
4. Single lesion multicentre trial group. A comparative trial of single dose chemotherapy in paucibacillary leprosy patients with two to three skin lesions. 2-3 lesion multicentre trial group. Indian J Lepr 2001; 73: 131-143.
5. Deshmukh AR, Dhurat RS, Jerajani UR. A comparative clinico-pathological study of single dose ROM in paucbacillary leprosy patients with 1-3 skin lesions. Indian J Lepr, 2003; 75: 209-217.
6. Ridley DS, Jopling WH. Classification of leprosy according to immunity: a 5 group system. Int J Lepr Other Mycobact Dis, 1966; 34: 255-273.
7. Report of the fifth meeting of the WHO technical advisory group on elimination of leprosy, Yangon, 9 and 10 February 2003, Geneva: World Health Organization; 2003 (WHO/CDS/CPE/CEE/2003.36).
8. Ji B, Saunderson P. Uniform MDT regimen for all leprosy patients- another example of wishful thinking. Lepr Rev, 2003; 74: 2-6. (Pubitemid 36358430)
9. Katoch K, Natarajan M, Bagga A, Katoch VM. Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT. Int J Lepr Other Mycobact Dis, 1989; 59: 248-254.
10. Jamet P, Ji B. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group. Int J Lepr Other Mycobact Dis, 1995; 63: 195-201.
11. Report of the Seventh Meeting of the WHO Technical Advisory Group on the elimination of leprosy. Geneva, 4-5 April 2005. New Delhi: World Health Organization; 2005.
12. st April 2006. New Delhi: World Health Organization; 2006.
13. th February, Hyderabad, India.
14. Katoch K, Natarajan M, Katoch VM et al. Chemotherapy trial in paucibacillary leprosy using clofazimine. Indian J Lepr, 1999; 71: 311-324. (Pubitemid 30006319)
15. Prasad PVS, Babu A, Kaviarasan PK et al. MDT-MB therapy in paucibacillary leprosy: a clinicopathological assessment. Indian J Dermatol Venereol Leprol, 2005; 71: 242-245. (Pubitemid 41191359)
16. Hastings RC, Jacobson RR, Trautman JR. Long term clinical toxicity studies with clofazimine (B663) in leprosy. Int J Lepr Other Mycobacerial Dis, 1976; 44: 287-293.
17. Emmanuel M, Gupte MD. Lesional characteristics and histopathology in Paucibaillary leprosy patients with 2 or 3 skin lesions: comparison between ROM and PB-MDT regimens. Indian J Lepr, 2005; 77: 21-25. (Pubitemid 40561860)
18. Job CK, Jayakumar J, Aschhoff M. Delayed resolution versus treatment failure in PB leprosy patients under six months fixed duration multidrug therapy. Indian J Lepr, 1997; 69: 131-142.
19. Single lesion multicentre trial group. Efficacy of single dose multi drug therapy for treatment of single lesion pauci bacillary leprosy. Indian J Lepr 1997; 69: 121-129.
20. Gelber RH, Balagon VF, Cellona RV. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low. Int J Lepr Other Mycobact Dis, 2004; 72: 493-500.
21. Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr Rev, 2000; 71: 144-153. (Pubitemid 30465827)
22. Ji B. Does there exist a subgroup of MB patients at greater risk of relapse after MDT? Lepr Rev, 2001; 72: 3-8.
23. Katoch VM. Advances in the diagnosis and treatment of leprosy. Exp. Rev. Mol. Med. 2002. http://www. expertreviews.org/02004763h.htm. Accessed on 3rd February 2007.